Nurix Therapeutics (NRIX) director awarded 31,250 stock options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. director Julia P. Gregory received a grant of stock options covering 31,250 shares of common stock. These options have an exercise price of $15.8600 per share and expire on May 14, 2036.

The award vests 100% on the earlier of the company’s next annual stockholder meeting or May 15, 2027, as long as she continues providing service to the company through that vesting date. This is a compensation-related grant, not an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider GREGORY JULIA P

Role null

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (right to buy)	31,250	$0.00	--

Holdings After Transaction: Director Stock Option (right to buy) — 31,250 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 31,250 options Exercise price: $15.8600 per share Expiration date: May 14, 2036 +3 more

6 metrics

Options granted 31,250 options Director stock option grant

Exercise price $15.8600 per share Stock option exercise price

Expiration date May 14, 2036 Option expiration

Underlying shares 31,250 shares Common stock underlying options

Post-transaction option holdings 31,250 options Total options from this award after grant

Vesting deadline May 15, 2027 Latest possible full vesting date

Key Terms

Director Stock Option, exercise price, vesting, annual meeting of the Issuer's stockholders

4 terms

Director Stock Option financial

"security_title: "Director Stock Option (right to buy)""

exercise price financial

"conversion_or_exercise_price: "15.8600" per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The stock option vests as to 100% of the award on the earlier of..."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of the Issuer's stockholders financial

"on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders"

Form 4 Insider Transactions: What Each Field Means →

05/15/2026 - 05:37 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GREGORY JULIA P

(Last)

(First)

(Middle)

C/O NURIX THERAPEUTICS, INC.

1600 SIERRA POINT PKWY

(Street)

BRISBANE

CALIFORNIA

94005

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Director Stock Option (right to buy)	$15.86	05/15/2026		A		31,250		⁽¹⁾	05/14/2036	Common Stock	31,250	$0	31,250	D

Explanation of Responses:

1. The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for Julia P. Gregory	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Nurix Therapeutics (NRIX) disclose about Julia P. Gregory in this Form 4?

Nurix Therapeutics reported that director Julia P. Gregory received a grant of 31,250 stock options. The options relate to common stock, have a fixed exercise price, and represent equity-based compensation rather than an open-market purchase or sale of existing shares.

How many Nurix Therapeutics (NRIX) stock options were granted to the director?

The director received 31,250 stock options linked to Nurix common stock. All 31,250 options were newly granted in this transaction and represent her total option holdings from this award after the grant, according to the filing’s reported post-transaction balance.

What is the exercise price of the stock options granted by Nurix Therapeutics (NRIX)?

The stock options granted to the director have an exercise price of $15.8600 per share. This means she can purchase Nurix common stock at that fixed price once the options vest, until they expire on the specified expiration date.

When do Julia P. Gregory’s Nurix (NRIX) stock options vest?

The options vest 100% on the earlier of the next annual meeting of Nurix’s stockholders or May 15, 2027. Vesting is conditioned on her continued service with the company through that vesting date, as described in the footnote to the filing.

When do the Nurix Therapeutics (NRIX) director stock options expire?

The options expire on May 14, 2036, giving a long exercise window after vesting. After that expiration date, any unexercised options will lapse and can no longer be used to acquire Nurix common stock at the stated exercise price.

Is this Nurix (NRIX) Form 4 a market purchase or sale by the director?

No, the Form 4 reflects a grant or award acquisition of stock options, not a market trade. The transaction code “A” and description show it is equity compensation, so no open-market buying or selling of common shares is reported in this filing.